Seq,
Don't have access to the report, only a summary on the FNArena site under Broker update .
It's pretty generic and doesn't provide much insight.
CIMB Securities (RBS Morgans), Date 14.5.13, Rating 1, Recommendation: Outperform; Target price: $0.27.
Commentary:
The broker expects the clinical timetable to be explained in more detail at the upcoming AGM. Some changes have been made to earnings forecasts for 2013 (eps -$1.4m) and 2014 (eps $1.0m). The Outperformance rating and 27 cents price target are maintained (from an earlier recommendation).
The trials for the patch are seen as the key catalyst and any delays or complications provide the risk to valuation, whilst additional agreements represent upside.
Hopefully, they might provide a further update following AGM, but as someone previously posted, they tend to set low targets and adjust up with movement in the SP.
- Forums
- ASX - By Stock
- rbs morgans weekly research report
Seq,Don't have access to the report, only a summary on the...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.338M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 36084472 | 0.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.3¢ | 35403846 | 21 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 36084472 | 0.002 |
18 | 52466742 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.003 | 35403846 | 21 |
0.004 | 27681763 | 16 |
0.005 | 8100000 | 7 |
0.006 | 8723435 | 8 |
0.007 | 13229103 | 6 |
Last trade - 16.12pm 11/10/2024 (20 minute delay) ? |
Featured News
AVE (ASX) Chart |
Day chart unavailable